Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Karl Bayer to Calcium-Calmodulin-Dependent Protein Kinase Type 2

This is a "connection" page, showing publications Karl Bayer has written about Calcium-Calmodulin-Dependent Protein Kinase Type 2.

 
Connection Strength
 
 
 
18.376
 
  1. Tullis JE, Larsen ME, Rumian NL, Freund RK, Boxer EE, Brown CN, Coultrap SJ, Schulman H, Aoto J, Dell'Acqua ML, Bayer KU. LTP induction by structural rather than enzymatic functions of CaMKII. Nature. 2023 Sep; 621(7977):146-153.
    View in: PubMed
    Score: 0.809
  2. Rumian NL, Freund RK, Dell'Acqua ML, Coultrap SJ, Bayer KU. Decreased nitrosylation of CaMKII causes aging-associated impairments in memory and synaptic plasticity in mice. Sci Signal. 2023 07 25; 16(795):eade5892.
    View in: PubMed
    Score: 0.804
  3. Larsen ME, Buonarati OR, Qian H, Hell JW, Bayer KU. Stimulating ?-adrenergic receptors promotes synaptic potentiation by switching CaMKII movement from LTD to LTP mode. J Biol Chem. 2023 06; 299(6):104706.
    View in: PubMed
    Score: 0.788
  4. Rumian NL, Brown CN, Hendry-Hofer TB, Rossetti T, Orfila JE, Tullis JE, Dwoskin LP, Buonarati OR, Lisman JE, Quillinan N, Herson PS, Bebarta VS, Bayer KU. Short-term CaMKII inhibition with tatCN19o does not erase pre-formed memory in mice and is neuroprotective in pigs. J Biol Chem. 2023 05; 299(5):104693.
    View in: PubMed
    Score: 0.787
  5. Cook SG, Rumian NL, Bayer KU. CaMKII T286 phosphorylation has distinct essential functions in three forms of long-term plasticity. J Biol Chem. 2022 09; 298(9):102299.
    View in: PubMed
    Score: 0.749
  6. Rumian NL, Chalmers NE, Tullis JE, Herson PS, Bayer KU. CaMKIIa knockout protects from ischemic neuronal cell death after resuscitation from cardiac arrest. Brain Res. 2021 12 15; 1773:147699.
    View in: PubMed
    Score: 0.711
  7. Tullis JE, Rumian NL, Brown CN, Bayer KU. The CaMKII K42M and K42R mutations are equivalent in suppressing kinase activity and targeting. PLoS One. 2020; 15(7):e0236478.
    View in: PubMed
    Score: 0.653
  8. Buonarati OR, Cook SG, Goodell DJ, Chalmers NE, Rumian NL, Tullis JE, Restrepo S, Coultrap SJ, Quillinan N, Herson PS, Bayer KU. CaMKII versus DAPK1 Binding to GluN2B in Ischemic Neuronal Cell Death after Resuscitation from Cardiac Arrest. Cell Rep. 2020 01 07; 30(1):1-8.e4.
    View in: PubMed
    Score: 0.628
  9. Bayer KU, Schulman H. CaM Kinase: Still Inspiring at 40. Neuron. 2019 08 07; 103(3):380-394.
    View in: PubMed
    Score: 0.610
  10. Cook SG, Goodell DJ, Restrepo S, Arnold DB, Bayer KU. Simultaneous Live Imaging of Multiple Endogenous Proteins Reveals a Mechanism for Alzheimer's-Related Plasticity Impairment. Cell Rep. 2019 04 16; 27(3):658-665.e4.
    View in: PubMed
    Score: 0.598
  11. Cook SG, Bourke AM, O'Leary H, Zaegel V, Lasda E, Mize-Berge J, Quillinan N, Tucker CL, Coultrap SJ, Herson PS, Bayer KU. Analysis of the CaMKIIa and ? splice-variant distribution among brain regions reveals isoform-specific differences in holoenzyme formation. Sci Rep. 2018 04 03; 8(1):5448.
    View in: PubMed
    Score: 0.556
  12. Woolfrey KM, O'Leary H, Goodell DJ, Robertson HR, Horne EA, Coultrap SJ, Dell'Acqua ML, Bayer KU. CaMKII regulates the depalmitoylation and synaptic removal of the scaffold protein AKAP79/150 to mediate structural long-term depression. J Biol Chem. 2018 02 02; 293(5):1551-1567.
    View in: PubMed
    Score: 0.543
  13. Goodell DJ, Zaegel V, Coultrap SJ, Hell JW, Bayer KU. DAPK1 Mediates LTD by Making CaMKII/GluN2B Binding LTP Specific. Cell Rep. 2017 06 13; 19(11):2231-2243.
    View in: PubMed
    Score: 0.526
  14. Goodell DJ, Benke TA, Bayer KU. Developmental restoration of LTP deficits in heterozygous CaMKIIa KO mice. J Neurophysiol. 2016 11 01; 116(5):2140-2151.
    View in: PubMed
    Score: 0.497
  15. Barcomb K, Hell JW, Benke TA, Bayer KU. The CaMKII/GluN2B Protein Interaction Maintains Synaptic Strength. J Biol Chem. 2016 07 29; 291(31):16082-9.
    View in: PubMed
    Score: 0.490
  16. Barcomb K, Goodell DJ, Arnold DB, Bayer KU. Live imaging of endogenous Ca??/calmodulin-dependent protein kinase II in neurons reveals that ischemia-related aggregation does not require kinase activity. J Neurochem. 2015 Nov; 135(4):666-73.
    View in: PubMed
    Score: 0.464
  17. Coultrap SJ, Zaegel V, Bayer KU. CaMKII isoforms differ in their specific requirements for regulation by nitric oxide. FEBS Lett. 2014 Dec 20; 588(24):4672-6.
    View in: PubMed
    Score: 0.440
  18. Coultrap SJ, Bayer KU. Nitric oxide induces Ca2+-independent activity of the Ca2+/calmodulin-dependent protein kinase II (CaMKII). J Biol Chem. 2014 Jul 11; 289(28):19458-65.
    View in: PubMed
    Score: 0.425
  19. Barcomb K, Buard I, Coultrap SJ, Kulbe JR, O'Leary H, Benke TA, Bayer KU. Autonomous CaMKII requires further stimulation by Ca2+/calmodulin for enhancing synaptic strength. FASEB J. 2014 Aug; 28(8):3810-9.
    View in: PubMed
    Score: 0.425
  20. Goodell DJ, Eliseeva TA, Coultrap SJ, Bayer KU. CaMKII binding to GluN2B is differentially affected by macromolecular crowding reagents. PLoS One. 2014; 9(5):e96522.
    View in: PubMed
    Score: 0.424
  21. Coultrap SJ, Freund RK, O'Leary H, Sanderson JL, Roche KW, Dell'Acqua ML, Bayer KU. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Rep. 2014 Feb 13; 6(3):431-7.
    View in: PubMed
    Score: 0.416
  22. Barcomb K, Coultrap SJ, Bayer KU. Enzymatic activity of CaMKII is not required for its interaction with the glutamate receptor subunit GluN2B. Mol Pharmacol. 2013 Dec; 84(6):834-43.
    View in: PubMed
    Score: 0.406
  23. Coultrap SJ, Bayer KU. CaMKII regulation in information processing and storage. Trends Neurosci. 2012 Oct; 35(10):607-18.
    View in: PubMed
    Score: 0.372
  24. Coultrap SJ, Barcomb K, Bayer KU. A significant but rather mild contribution of T286 autophosphorylation to Ca2+/CaM-stimulated CaMKII activity. PLoS One. 2012; 7(5):e37176.
    View in: PubMed
    Score: 0.370
  25. Coultrap SJ, Bayer KU. Improving a natural CaMKII inhibitor by random and rational design. PLoS One. 2011; 6(10):e25245.
    View in: PubMed
    Score: 0.354
  26. O'Leary H, Liu WH, Rorabaugh JM, Coultrap SJ, Bayer KU. Nucleotides and phosphorylation bi-directionally modulate Ca2+/calmodulin-dependent protein kinase II (CaMKII) binding to the N-methyl-D-aspartate (NMDA) receptor subunit GluN2B. J Biol Chem. 2011 Sep 09; 286(36):31272-81.
    View in: PubMed
    Score: 0.349
  27. Coultrap SJ, Vest RS, Ashpole NM, Hudmon A, Bayer KU. CaMKII in cerebral ischemia. Acta Pharmacol Sin. 2011 Jul; 32(7):861-72.
    View in: PubMed
    Score: 0.347
  28. Buard I, Coultrap SJ, Freund RK, Lee YS, Dell'Acqua ML, Silva AJ, Bayer KU. CaMKII "autonomy" is required for initiating but not for maintaining neuronal long-term information storage. J Neurosci. 2010 Jun 16; 30(24):8214-20.
    View in: PubMed
    Score: 0.324
  29. Vest RS, O'Leary H, Coultrap SJ, Kindy MS, Bayer KU. Effective post-insult neuroprotection by a novel Ca(2+)/ calmodulin-dependent protein kinase II (CaMKII) inhibitor. J Biol Chem. 2010 Jul 02; 285(27):20675-82.
    View in: PubMed
    Score: 0.321
  30. Coultrap SJ, Buard I, Kulbe JR, Dell'Acqua ML, Bayer KU. CaMKII autonomy is substrate-dependent and further stimulated by Ca2+/calmodulin. J Biol Chem. 2010 Jun 04; 285(23):17930-7.
    View in: PubMed
    Score: 0.319
  31. Vest RS, O'Leary H, Bayer KU. Differential regulation by ATP versus ADP further links CaMKII aggregation to ischemic conditions. FEBS Lett. 2009 Nov 19; 583(22):3577-81.
    View in: PubMed
    Score: 0.309
  32. Vest RS, Davies KD, O'Leary H, Port JD, Bayer KU. Dual mechanism of a natural CaMKII inhibitor. Mol Biol Cell. 2007 Dec; 18(12):5024-33.
    View in: PubMed
    Score: 0.269
  33. Buonarati OR, Miller AP, Coultrap SJ, Bayer KU, Reichow SL. Conserved and divergent features of neuronal CaMKII holoenzyme structure, function, and high-order assembly. Cell Rep. 2021 12 28; 37(13):110168.
    View in: PubMed
    Score: 0.180
  34. Opazo P, Viana da Silva S, Carta M, Breillat C, Coultrap SJ, Grillo-Bosch D, Sainlos M, Coussen F, Bayer KU, Mulle C, Choquet D. CaMKII Metaplasticity Drives A? Oligomer-Mediated Synaptotoxicity. Cell Rep. 2018 06 12; 23(11):3137-3145.
    View in: PubMed
    Score: 0.141
  35. Myers JB, Zaegel V, Coultrap SJ, Miller AP, Bayer KU, Reichow SL. The CaMKII holoenzyme structure in activation-competent conformations. Nat Commun. 2017 06 07; 8:15742.
    View in: PubMed
    Score: 0.131
  36. Deng G, Orfila JE, Dietz RM, Moreno-Garcia M, Rodgers KM, Coultrap SJ, Quillinan N, Traystman RJ, Bayer KU, Herson PS. Autonomous CaMKII Activity as a Drug Target for Histological and Functional Neuroprotection after Resuscitation from Cardiac Arrest. Cell Rep. 2017 01 31; 18(5):1109-1117.
    View in: PubMed
    Score: 0.128
  37. Dosemeci A, Toy D, Burch A, Bayer KU, Tao-Cheng JH. CaMKII-mediated displacement of AIDA-1 out of the postsynaptic density core. FEBS Lett. 2016 09; 590(17):2934-9.
    View in: PubMed
    Score: 0.124
  38. Khan S, Conte I, Carter T, Bayer KU, Molloy JE. Multiple CaMKII Binding Modes to the Actin Cytoskeleton Revealed by Single-Molecule Imaging. Biophys J. 2016 Jul 26; 111(2):395-408.
    View in: PubMed
    Score: 0.124
  39. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. NMDA-induced accumulation of Shank at the postsynaptic density is mediated by CaMKII. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):808-11.
    View in: PubMed
    Score: 0.107
  40. Thein S, Tao-Cheng JH, Li Y, Bayer KU, Reese TS, Dosemeci A. CaMKII mediates recruitment and activation of the deubiquitinase CYLD at the postsynaptic density. PLoS One. 2014; 9(3):e91312.
    View in: PubMed
    Score: 0.105
  41. Liu X, Liu Y, Zhong P, Wilkinson B, Qi J, Olsen CM, Bayer KU, Liu QS. CaMKII activity in the ventral tegmental area gates cocaine-induced synaptic plasticity in the nucleus accumbens. Neuropsychopharmacology. 2014 Mar; 39(4):989-99.
    View in: PubMed
    Score: 0.102
  42. Yang Y, Tao-Cheng JH, Bayer KU, Reese TS, Dosemeci A. Camkii-mediated phosphorylation regulates distributions of Syngap-a1 and -a2 at the postsynaptic density. PLoS One. 2013; 8(8):e71795.
    View in: PubMed
    Score: 0.101
  43. Tao-Cheng JH, Yang Y, Bayer KU, Reese TS, Dosemeci A. Effects of CaMKII inhibitor tatCN21 on activity-dependent redistribution of CaMKII in hippocampal neurons. Neuroscience. 2013 Aug 06; 244:188-96.
    View in: PubMed
    Score: 0.098
  44. Loweth JA, Li D, Cortright JJ, Wilke G, Jeyifous O, Neve RL, Bayer KU, Vezina P. Persistent reversal of enhanced amphetamine intake by transient CaMKII inhibition. J Neurosci. 2013 Jan 23; 33(4):1411-6.
    View in: PubMed
    Score: 0.097
  45. Sanhueza M, Fernandez-Villalobos G, Stein IS, Kasumova G, Zhang P, Bayer KU, Otmakhov N, Hell JW, Lisman J. Role of the CaMKII/NMDA receptor complex in the maintenance of synaptic strength. J Neurosci. 2011 Jun 22; 31(25):9170-8.
    View in: PubMed
    Score: 0.087
  46. Marsden KC, Shemesh A, Bayer KU, Carroll RC. Selective translocation of Ca2+/calmodulin protein kinase IIalpha (CaMKIIalpha) to inhibitory synapses. Proc Natl Acad Sci U S A. 2010 Nov 23; 107(47):20559-64.
    View in: PubMed
    Score: 0.083
  47. Cipolletta E, Monaco S, Maione AS, Vitiello L, Campiglia P, Pastore L, Franchini C, Novellino E, Limongelli V, Bayer KU, Means AR, Rossi G, Trimarco B, Iaccarino G, Illario M. Calmodulin-dependent kinase II mediates vascular smooth muscle cell proliferation and is potentiated by extracellular signal regulated kinase. Endocrinology. 2010 Jun; 151(6):2747-59.
    View in: PubMed
    Score: 0.080
  48. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA, Cohen MB. Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther. 2007 May; 6(5):732-42.
    View in: PubMed
    Score: 0.064
  49. O'Leary H, Lasda E, Bayer KU. CaMKIIbeta association with the actin cytoskeleton is regulated by alternative splicing. Mol Biol Cell. 2006 Nov; 17(11):4656-65.
    View in: PubMed
    Score: 0.062
  50. O'Leary H, Sui X, Lin PJ, Volpe P, Bayer KU. Nuclear targeting of the CaMKII anchoring protein alphaKAP is regulated by alternative splicing and protein kinases. Brain Res. 2006 May 01; 1086(1):17-26.
    View in: PubMed
    Score: 0.061
  51. Bayer KU, LeBel E, McDonald GL, O'Leary H, Schulman H, De Koninck P. Transition from reversible to persistent binding of CaMKII to postsynaptic sites and NR2B. J Neurosci. 2006 Jan 25; 26(4):1164-74.
    View in: PubMed
    Score: 0.060
  52. Bayer KU, De Koninck P, Schulman H. Alternative splicing modulates the frequency-dependent response of CaMKII to Ca(2+) oscillations. EMBO J. 2002 Jul 15; 21(14):3590-7.
    View in: PubMed
    Score: 0.047
  53. Bayer KU, Schulman H. Regulation of signal transduction by protein targeting: the case for CaMKII. Biochem Biophys Res Commun. 2001 Dec 21; 289(5):917-23.
    View in: PubMed
    Score: 0.045
  54. Bayer KU, De Koninck P, Leonard AS, Hell JW, Schulman H. Interaction with the NMDA receptor locks CaMKII in an active conformation. Nature. 2001 Jun 14; 411(6839):801-5.
    View in: PubMed
    Score: 0.043
  55. Chalmers NE, Yonchek J, Steklac KE, Ramsey M, Bayer KU, Herson PS, Quillinan N. Calcium/Calmodulin-Dependent Kinase (CaMKII) Inhibition Protects Against Purkinje Cell Damage Following CA/CPR in Mice. Mol Neurobiol. 2020 Jan; 57(1):150-158.
    View in: PubMed
    Score: 0.038
  56. Bayer KU, L?hler J, Schulman H, Harbers K. Developmental expression of the CaM kinase II isoforms: ubiquitous gamma- and delta-CaM kinase II are the early isoforms and most abundant in the developing nervous system. Brain Res Mol Brain Res. 1999 Jun 18; 70(1):147-54.
    View in: PubMed
    Score: 0.038
  57. Bayer KU, Harbers K, Schulman H. alphaKAP is an anchoring protein for a novel CaM kinase II isoform in skeletal muscle. EMBO J. 1998 Oct 01; 17(19):5598-605.
    View in: PubMed
    Score: 0.036
  58. Bayer KU, L?hler J, Harbers K. An alternative, nonkinase product of the brain-specifically expressed Ca2+/calmodulin-dependent kinase II alpha isoform gene in skeletal muscle. Mol Cell Biol. 1996 Jan; 16(1):29-36.
    View in: PubMed
    Score: 0.030
  59. Bernard PB, Castano AM, Bayer KU, Benke TA. Necessary, but not sufficient: insights into the mechanisms of mGluR mediated long-term depression from a rat model of early life seizures. Neuropharmacology. 2014 Sep; 84:1-12.
    View in: PubMed
    Score: 0.026
  60. Boguslavsky S, Chiu T, Foley KP, Osorio-Fuentealba C, Antonescu CN, Bayer KU, Bilan PJ, Klip A. Myo1c binding to submembrane actin mediates insulin-induced tethering of GLUT4 vesicles. Mol Biol Cell. 2012 Oct; 23(20):4065-78.
    View in: PubMed
    Score: 0.024
  61. Illario M, Cavallo AL, Bayer KU, Di Matola T, Fenzi G, Rossi G, Vitale M. Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation. J Biol Chem. 2003 Nov 14; 278(46):45101-8.
    View in: PubMed
    Score: 0.013
  62. Fink CC, Bayer KU, Myers JW, Ferrell JE, Schulman H, Meyer T. Selective regulation of neurite extension and synapse formation by the beta but not the alpha isoform of CaMKII. Neuron. 2003 Jul 17; 39(2):283-97.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)